Skip to content
Basket0
Basket

Your basket is empty.

Your basket is empty.

View basket
☰

Provera

Provera
In stock
5mg · 10mg
from 12,99 £
Strength
Pack size — the bigger the pack, the cheaper the tablet
16,51 £13,75 £
0,69 £ per tablet

In brief

  • Provera is a prescription-only medicine in the UK and must be dispensed by a pharmacy with a prescription.
  • Provera (medroxyprogesterone acetate) is a progestogen used for menstrual disorders (abnormal uterine bleeding, secondary amenorrhoea), endometrial protection in HRT and, in injectable form (Depo‑Provera/Sayana Press), contraception; it works by acting on progesterone receptors to stabilise the endometrium, oppose oestrogen-driven growth and, for the injectable, suppress ovulation.
  • Usual dosages include oral tablets 5–10 mg daily for 5–10 days for abnormal uterine bleeding or 5–10 mg daily for 12–14 days per month with oestrogen in HRT; injectable contraception is Depo‑Provera 150 mg IM every 3 months or Sayana Press 104 mg subcutaneously every 3 months. Tablets are also available in 2.5 mg, 5 mg and 10 mg strengths.
  • Administration is oral for tablets and intramuscular or subcutaneous injection for contraceptive depot preparations (prefilled syringes or vials for IM/SQ use).
  • Onset: oral effects on bleeding patterns are often seen within a few days; contraceptive injections suppress ovulation rapidly (can act within 24–72 hours and are immediately effective if administered at the correct time in the cycle; otherwise use backup contraception as advised).
  • Duration of action: oral effects persist while the drug is taken (short courses of 5–10 days or monthly 12–14 day cycles for HRT); depot injections provide contraception for approximately 12–13 weeks (about 3 months) per dose.
  • Alcohol warning: there is no specific contraindication with ordinary alcohol intake, but alcohol may exacerbate side effects such as drowsiness or mood changes — avoid heavy drinking and discuss alcohol use with your prescriber.
  • The most common side effects are menstrual irregularities (spotting or amenorrhoea), weight gain, headache, breast tenderness, bloating or nausea, mood changes and, for injectables, injection‑site reactions.
  • Would you like to try Provera without a prescription?

Basic Provera information

  • INN (international nonproprietary name): Medroxyprogesterone acetate.
  • Brand names available in the United Kingdom: Provera and generics; injectable preparations Depo‑Provera and Sayana Press.
  • ATC code: G03DA02.
  • Forms and dosages: Oral tablets 2.5 mg, 5 mg, 10 mg; injectables 104 mg/0.65 mL (Sayana Press, subcutaneous) and 150 mg/mL (Depo‑Provera, intramuscular).
  • Manufacturers in the United Kingdom: Pfizer.
  • Registration status in the United Kingdom: Prescription-only medicine (POM).
  • OTC / Rx classification: Prescription only (Rx).

Critical warnings and restrictions (safety first)

High‑risk groups (elderly, pregnancy, chronic illness)

Are you pregnant or might be pregnant? Confirm pregnancy status before starting Provera because medroxyprogesterone acetate is contraindicated in pregnancy.

Medroxyprogesterone acetate is contraindicated in patients with active or prior thromboembolic disease, known or suspected breast or genital malignancy, undiagnosed vaginal bleeding, and significant liver dysfunction.

Elderly patients need extra caution because of increased thromboembolic and cognitive risks and because routine dose reduction is not recommended.

People with chronic illness — for example diabetes with vascular complications, uncontrolled hypertension, epilepsy or severe migraine — should have specialist review and documented informed consent before starting Provera.

  • Use this clinic checklist before prescribing: pregnancy test, VTE risk assessment, breast/genital examination as indicated, review of liver function, medication reconciliation, mental‑health screen.
Contraindication Immediate action / monitoring
Pregnancy Do not prescribe; confirm negative pregnancy test before starting.
Active/prior VTE (DVT/PE) Contraindicated; refer to specialist and document decision.
Breast or genital malignancy Contraindicated; arrange appropriate investigations and referrals.
Significant liver dysfunction Contraindicated; avoid use until liver status clarified.

Interaction with activities (driving, workplace safety under UK law)

Some people experience side effects that can impair concentration or alertness such as drowsiness, dizziness or marked mood changes.

If a patient reports drowsiness, dizziness or impaired concentration after taking Provera they must not drive, operate heavy machinery, or carry out safety‑critical work until these symptoms resolve.

Advise patients to follow the Highway Code and their workplace safety rules, and record the safety advice in the clinical notes.

Q&A — “Can I drive after taking it in the UK?”

Short answer: Usually yes, but if you feel drowsy, dizzy or impaired you must not drive.

Follow the UK Highway Code and workplace safety rules and document the advice in patient records.

Usage basics

INN, brand names available in the United Kingdom

What is Provera? The International Nonproprietary Name (INN) is medroxyprogesterone acetate.

UK brands include Provera for oral use and Depo‑Provera/Sayana Press for injectable contraception.

  • INN → medroxyprogesterone acetate.
  • Oral brand → Provera.
  • Injectable brands → Depo‑Provera, Sayana Press.
  • Legal classification (POM, P, GSL)

    Provera and injectable medroxyprogesterone acetate are prescription‑only medicines in the UK.

    In the UK context supply and use must follow national licensing and prescribing frameworks and a valid prescription is required for dispensing.

    Electronic prescribing and NHS repeat dispensing are commonly used in primary care for contraception and HRT medicines.

    Dosing guide

    Standard regimens (NHS guidelines)

    Typical oral regimens for secondary amenorrhoea or abnormal uterine bleeding are 5–10 mg daily for 5–10 days, often started around day 16–21 of the cycle.

    For endometrial protection when oestrogen is prescribed, oral medroxyprogesterone acetate is commonly given 5–10 mg daily for 12–14 consecutive days each month.

    Injectable contraceptive regimens are Depo‑Provera 150 mg IM every 13 weeks and Sayana Press 104 mg subcutaneously every 13 weeks.

    Indication Usual dose Duration Monitoring points
    Abnormal uterine bleeding 5–10 mg oral daily 5–10 days (per cycle) Bleeding response; liver tests if indicated
    Endometrial protection (with oestrogen) 5–10 mg oral daily 12–14 days each month Monitor uterine bleeding; cancer screening per guidelines
    Contraception (depot) 150 mg IM or 104 mg SQ Every 13 weeks Discuss bone health if used >2 years; weight, mood checks

    Adjustments for comorbidities

    There is no routine elderly dose reduction but assess thromboembolic and cognitive risk before prescribing.

    Avoid use in significant liver impairment because medroxyprogesterone acetate is hepatically metabolised and contraindicated in severe liver disease.

    Children are not routinely indicated and any use should be specialist‑guided and individually dosed.

    For prolonged injectable use beyond two years monitor mood, weight, blood pressure and discuss bone health and DEXA scanning where risk factors are present.

    Q&A — “What if I miss a dose?”

    Oral tablet: take the missed dose as soon as remembered on the same day; if it is near the time for the next dose skip the missed dose — do not double up.

    Injectable: attend for the injection as soon as possible and use backup contraception if the injection is delayed beyond the recommended window.

    Interaction chart

    Food and drinks (alcohol, tea/coffee, diet habits)

    There are no major food interactions documented with medroxyprogesterone acetate tablets or depot injections.

    Alcohol can worsen mood changes and headache and should be limited if patients experience these side effects.

    Maintain a healthy diet and consider calcium and vitamin D supplementation if using depot injections long‑term because of bone density considerations.

    • Alcohol caution — may worsen mood/headache and contribute to weight gain.
    • Smoking — increases overall cardiovascular risk and compounds VTE concerns.
    • Nutrition — adequate calcium and vitamin D advised for long‑term depot users.
    • Caffeine — may exacerbate anxiety or headache in susceptible individuals.

    Common drug conflicts

    Hepatic enzyme inducers such as carbamazepine, rifampicin and some antiretrovirals can reduce progestogen levels and may affect efficacy.

    Concurrent central nervous system depressants or sedating antidepressants can increase drowsiness or dizziness when combined with progestogens.

    Always perform medication reconciliation at every visit and report suspected adverse reactions via the MHRA Yellow Card scheme.

    • Review anticonvulsants, HIV medicines and rifampicin.
    • Ask about herbal remedies such as St John’s wort which can induce hepatic enzymes.
    • Check anticoagulants and antidepressants for interaction potential and adjust monitoring accordingly.

    Legal status and availability in the UK

    In our online pharmacy, Provera is available without a prescription, with discreet delivery to the United Kingdom in 5‑14 days.

    Mechanism and pharmacology

    Simplified explanation

    Medroxyprogesterone acetate is a synthetic progestogen that acts on progesterone receptors to stabilise the endometrium and reduce uterine bleeding.

    Depot injections additionally suppress ovulation, providing a reliable contraceptive effect for about three months per dose.

    ATC code is G03DA02 and the classification is progestogens.

    Clinical terms

  • Progestogen → a synthetic progesterone‑like hormone.
  • Depot → a long‑acting injectable formulation that releases drug over time.
  • Amenorrhoea → absence of menstrual periods.
  • Medroxyprogesterone acetate undergoes hepatic metabolism and the half‑life varies by formulation, with depot forms providing sustained systemic exposure.

    Because of hepatic metabolism, interactions with enzyme inducers are clinically relevant and liver disease is a contraindication.

    Indications and off‑label uses

    MHRA‑approved uses

    Authorised uses include treatment of abnormal uterine bleeding and secondary amenorrhoea, endometrial protection when combined with oestrogen in HRT, and contraceptive use via depot injections.

    Standard dosages per indication are oral 5–10 mg for bleeding/amenorrhoea and depot injections 150 mg IM or 104 mg SQ every three months for contraception.

    Off‑label practices in NHS and private care

    Off‑label use can include period delay in specific circumstances or symptom control in endometriosis, but such uses require documented rationale and informed consent.

    • Clinician checklist for off‑label use: state clinical reason, review alternatives, document informed consent, and set a monitoring plan.

    Alternatives matrix

    NHS prescribing alternatives (comparison table)

    Drug Typical dose Pros Cons UK availability
    Norethisterone Not specified Effective for bleeding control; oral option May have androgenic effects in some patients Available
    Micronised progesterone (Utrogestan) Not specified Physiological progestogen; preferred by some for mood profile Oral bioavailability issues; may be less widely used Available
    Levonorgestrel (various) Not specified Well‑established contraceptive options; IUS provides local effect Route and side‑effect profiles vary Available

    Pros and cons checklist

    • Discuss efficacy for the indication and likely time to effect.
    • Review side‑effect profile including mood and weight.
    • Assess thrombosis risk and suitability in VTE‑prone patients.
    • Consider bone health, particularly with depot contraception used beyond two years.
    • Consider the patient’s desire for future fertility — depot injections can delay return to fertility.

    Common questions (patient FAQs from UK consultations)

    • Will Provera stop my period permanently? — Usually it regulates or induces a withdrawal bleed; long‑term depot contraception can cause amenorrhoea that is generally reversible on cessation.
    • Is fertility affected long‑term? — Fertility usually returns after stopping oral treatment; depot injections may delay return of fertility by several months but are generally reversible.
    • Can I take it with my antidepressant or anticonvulsant? — Check for interactions and medication‑specific issues; specialist review may be needed for enzyme‑inducing anticonvulsants or interacting antidepressants.
    • When should I seek urgent help? — Seek urgent care for signs of DVT/PE, severe chest pain, sudden weakness, jaundice or severe depressive symptoms.

    Registration and regulation

    MHRA approval process

    Medicines must be licensed with a Summary of Product Characteristics and patient information leaflet and clinicians should consult the SmPC for details on indications and contraindications.

    Medroxyprogesterone acetate preparations are prescription‑only medicines (POM) in the UK.

    NHS prescribing framework

    Prescribers must document the indication, counselling and follow‑up arrangements and local sexual health service protocols usually set pathways for depot contraception administration.

    • Documentation checklist: consent, baseline checks, planned follow‑up date, and Yellow Card reporting if an adverse event occurs.

    Storage and handling (United Kingdom households and clinics)

    Home storage (cold/damp climate)

    Store oral tablets at or below 25–30°C, keep them in the original packaging and protect from damp and children.

    Injectable products should be stored at 15–30°C, protected from light and must not be frozen.

    Clinical handling and transport

    Clinics should verify batch and expiry on arrival, store injectables per manufacturer instructions and document lot numbers for pharmacovigilance.

    Aseptic technique is required for IM or SQ administration and provide patients with safe disposal advice for sharps if needed.

  • Expiry date → the last usable date on the packaging.
  • Cold chain → maintenance of required temperatures during transport and storage.
  • Guidelines for proper use (patient safety and pharmacist counselling)

    UK pharmacist counselling style

    Open with the patient’s primary concern and confirm the indication for Provera before counselling.

    Review contraindications — especially VTE history, breast cancer and liver disease — and check concurrent medicines for interactions such as enzyme inducers or CNS depressants.

    Explain common side effects including menstrual changes, possible weight change and mood alterations and advise on driving and work safety if drowsiness occurs.

    • Counselling checklist: indication, contraindications, medicine review, side effects, follow‑up plan and documentation per GPhC standards.

    NHS patient safety advice

    Advise patients when to seek urgent care: symptoms of DVT/PE, severe chest pain, sudden neurological changes, jaundice or severe depression.

    Routine follow‑up should include blood pressure, weight and mood assessment at three months and annually for long‑term use.

    Discuss bone health if depot contraception is to be used for more than two years and consider DEXA scanning when other risk factors are present.

    Encourage reporting of suspected adverse reactions via the MHRA Yellow Card scheme and follow local care pathways for switching treatments.

    Delivery across the United Kingdom

    City Region Delivery Time
    London Greater London 9–21 days
    Birmingham West Midlands 9–21 days
    Manchester Greater Manchester 9–21 days
    Glasgow Scotland 9–21 days
    Leeds West Yorkshire 9–21 days
    Edinburgh Scotland 9–21 days
    Liverpool Merseyside 9–21 days
    Bristol South West England 9–21 days
    Sheffield South Yorkshire 9–21 days
    Newcastle Upon Tyne North East England 9–21 days
    Belfast Northern Ireland 9–21 days
    Cardiff Wales 9–21 days
    Leicester Leicestershire 9–21 days
    Coventry West Midlands 9–21 days

    Related products